Xcellerex’ products have reportedly been used in more than 20 therapeutic proteins and vaccines.
Biomanufacturing professionals are enthusiastic about continuous processing because they believe it will have a significant impact on how their customers bring therapies to market, delivering them to patients faster and more cost effectively. MilliporeSigma officials...
BioMimetic Strengthens Arrangement with Novartis for Exclusive Supply of Recombinant Human Platelet-Derived Growth Factor
Firm believes that it now has a stronghold in the development of rhPDGF-BB for orthopedic indications. BioMimetic Therapeutics has amended its manufacturing and supply agreement with Novartis Vaccines and Diagnostics for the supply of bulk...
AGC plans to install an additional twelve 2,000L single-use animal-cell bioreactors at their Seattle AGC Biologics site, as well as establish a new contract development and manufacturing facility for microbial manufacturing.
Microbial culture systems dominate industrial-scale production, where the large volumes rule out the possibility of employing mammalian cells. Although gigantic projects such as algae ponds engineered to literally generate tons of product lie in the future, microbial systems are currently capable of producing substantial volumes of bulk chemicals at levels competitive with conventional chemical synthetic protocols.
Funds will support development, validation, vaccine trials, and regulatory clearance.
Centers aims to automate protocols for exome-capture and library-preparation workflows.
Aldevron was selected to produce CureLab Oncology’s DNA-based vaccine for cancer treatment.